Literature DB >> 15682442

DNA replication licensing in peripheral B-cell lymphoma.

Ellen C Obermann1, Kathryn Leigh Eward, Ahmet Dogan, Elizabeth A Paul, Marco Loddo, Philippa Munson, Gareth H Williams, Kai Stoeber.   

Abstract

Peripheral B-cell lymphomas representing 90% of lymphoid neoplasms are divided into low- and high-growth fraction lymphomas. Here we investigate regulation of DNA replication licensing during B-cell lymphomagenesis. Combined analysis of origin licensing factors Mcm2 and geminin with the proliferation marker Ki67 in SLL/CLL, MCL, DLBCL and Burkitt lymphoma reveals for the first time the precise cell cycle state of these entities. Given that tight Mcm2 downregulation defines the quiescent state (G0) and that both high- and low-growth fraction lymphomas express Mcm2, the data demonstrate that neoplastic lymphocytes of SLL/CLL and MCL reside in an "in-cycle" G1 state and not in G0 as previously thought. Absence of the S/G2/M phase marker geminin in SLL/CLL and MCL further indicates failure of cell cycle progression in these tumours. In contrast, the high-growth fraction lymphomas DLBCL and Burkitt lymphoma exhibit differential expression of geminin, with the geminin/Ki67 ratio increasing for more aggressive neoplasms in keeping with a shortened G1 phase and thus representing an important discriminator for differential diagnosis. These data provide new insights into abrogation of cell cycle control during B cell lymphomagenesis and suggest that combined analysis of origin licensing factors may contribute to improved treatment decisions and prognosis in haematopoietic malignancies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15682442     DOI: 10.1002/path.1695

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase.

Authors:  Ellen C Obermann; Philip Went; Alexandar Tzankov; Stefano A Pileri; Ferdinand Hofstaedter; Joerg Marienhagen; Robert Stoehr; Stephan Dirnhofer
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

2.  [Use of marker systems in the treatment of bladder cancer].

Authors:  M Burger; F Vom Dorp
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

3.  DNA replication licensing factors and aneuploidy are linked to tumor cell cycle state and clinical outcome in penile carcinoma.

Authors:  Oliver J Kayes; Marco Loddo; Nimish Patel; Pranav Patel; Suks Minhas; Gareth Ambler; Alex Freeman; Alex Wollenschlaeger; David J Ralph; Kai Stoeber; Gareth H Williams
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

4.  Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis.

Authors:  Ellen C Obermann; Philip Went; Annette Zimpfer; Alexandar Tzankov; Peter J Wild; Robert Stoehr; Stefano A Pileri; Stephan Dirnhofer
Journal:  BMC Cancer       Date:  2005-12-20       Impact factor: 4.430

5.  Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells.

Authors:  S B Wharton; E Maltby; D A Jellinek; D Levy; N Atkey; S Hibberd; D Crimmins; K Stoeber; G H Williams
Journal:  Acta Neuropathol       Date:  2006-12-09       Impact factor: 17.088

6.  Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma.

Authors:  C Schrader; D Janssen; W Klapper; J-U Siebmann; P Meusers; G Brittinger; M Kneba; M Tiemann; R Parwaresch
Journal:  Br J Cancer       Date:  2005-10-17       Impact factor: 7.640

7.  Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer.

Authors:  T J Dudderidge; S R McCracken; M Loddo; T R Fanshawe; J D Kelly; D E Neal; H Y Leung; G H Williams; K Stoeber
Journal:  Br J Cancer       Date:  2007-04-03       Impact factor: 7.640

8.  MCM10 overexpression implicates adverse prognosis in urothelial carcinoma.

Authors:  Wei-Ming Li; Chun-Nung Huang; Hung-Lung Ke; Ching-Chia Li; Yu-Ching Wei; Hsin-Chih Yeh; Lin-Li Chang; Chun-Hsiung Huang; Peir-In Liang; Bi-Wen Yeh; Ti-Chun Chan; Chien-Feng Li; Wen-Jeng Wu
Journal:  Oncotarget       Date:  2016-11-22

9.  Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer.

Authors:  M Loddo; S R Kingsbury; M Rashid; I Proctor; C Holt; J Young; S El-Sheikh; M Falzon; K L Eward; T Prevost; R Sainsbury; K Stoeber; G H Williams
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

Review 10.  MCMs in Cancer: Prognostic Potential and Mechanisms.

Authors:  Si Yu; Guanqun Wang; Yue Shi; Haifeng Xu; Yongchang Zheng; Yang Chen
Journal:  Anal Cell Pathol (Amst)       Date:  2020-02-03       Impact factor: 2.916

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.